COVID-19 vaccine-associated lymphadenopathy in breast imaging recipients: A review of literature

Authors

Roxanne T. Aleman, Advocate Aurora HealthFollow
Julia Rauch, Internal Medicine, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, USA.
Janvi Desai, Internal Medicine, University of Illinois College of Medicine, Chicago, USA.
Joumana T. Chaiban, Advocate Aurora HealthFollow

Recommended Citation

Aleman RT, Rauch J, Desai J, Chaiban JT. COVID-19 Vaccine-Associated Lymphadenopathy in Breast Imaging Recipients: A Review of Literature. Cureus. 2022;14(7):e26845. Published 2022 Jul 14. doi:10.7759/cureus.26845

Affiliations

Advocate Christ Medical Center

Abstract

The unpredictability of the coronavirus disease 2019 (COVID-19) pandemic has created an ongoing global healthcare crisis. Implementation of a mass vaccination program to accelerate disease control remains in progress. Although injection site soreness, fatigue, and fever are the most common adverse reactions reported after a COVID-19 vaccination, ipsilateral lymph node enlargement has increasingly been observed. In patients undergoing routine screening and surveillance for breast cancer, interpreting lymphadenopathy (LAP) is challenging in the setting of a recent COVID-19 vaccination. With a growing proportion of the population receiving the vaccine, a multifaceted approach is necessary to avoid unnecessary and costly workup. In this comprehensive review, we summarize the existing literature on COVID-19 vaccine-associated LAP in breast imaging patients.

Type

Article

PubMed ID

35974844